AXIOS November 27, 2024
The Biden administration’s eleventh hour move to expand Medicare coverage for anti-obesity drugs is likely to be popular among seniors, putting the Trump administration — which would ultimately decide whether to carry out the expansion — in the hot seat.
Why it matters: The buzzy class of drugs known as GLP-1 agonists have been hailed as game changers amid an obesity crisis tied to chronic diseases.
- But the drugs are pricey, and insurers, advocacy groups and policymakers warn that opening up coverage for them could be a recipe for runaway costs in an already financially taxed system.
Driving the news: Under current law, Medicare is barred by Congress from covering drugs for weight loss. They’re covered only as...
Today's Sponsors
Today's Sponsor